Somite Raises $5.3M to Develop AI Platform for Stem Cell Biology

Somite Raises $5.3M in Pre-Seed Funding

Key Highlights:

• Company Overview: Somite is a Boston-based developer of AI for stem cell biology.
• Funding Round: Raised $5.3 million in Pre-Seed funding.
• Investors: Led by TechAviv, with participation from Next Coast Ventures, Trust Ventures, Texas Venture Partners, Lerer Hippeau, and others.
• AlphaStem AI Platform: Funds will be used to continue development of Somite's proprietary AlphaStem AI platform.

Somite's Target Market

• Biotechnology and Stem Cell Research: Companies and researchers focused on stem cell biology and cell therapies.
• Cell Therapy Development: Organizations seeking to develop new cell therapies for diseases such as diabetes, obesity, and muscular dystrophies.
• AI in Biomedical Research: Companies and institutions leveraging AI to advance biomedical research and accelerate therapy development.

What Somite Needs to Buy

• Research and Development: Investments in research and development to further enhance the AlphaStem AI platform and advance stem cell biology capabilities.
• Data Analysis and Computational Resources: Partnerships with data analysis and computational resources providers to support the processing and analysis of large-scale biological data.
• Collaborations with Stem Cell Experts: Collaborations with stem cell experts and researchers to leverage their expertise and advance cell therapy development.